In September 2007, W. Scott Melvin, MD, was the first surgeon in the United States to use a FDA-approved device for translumenal surgical treatment of Gastroesophageal Reflux Disease (GERD). CMIS faculty have been in the forefront of GERD, Barrett’s esophagus, and esophageal cancer treatment, participating in FDA-approved trials of new treatments, evaluating the efficacy of established minimally invasive surgery, and rigorously comparing the various treatment options for safety and efficacy.
GERD References
Smith CD, Bejarano PA, Melvin WS, Patti MG, Muthusamy R, Dunkin BJ. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 2007 Apr;21(4):560-569.
Dunkin BJ, Martinez J, Bejarano PA, Smith CD, Chang K, Livingstone AS, Melvin WS. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc 2006 Jan;20(1):125-130.
Wright As, Gould JC, Melvin WS. Computer-assisted robotic antireflux surgery. Minerva Gastroenterol Dietol 2004 Sep;50(3):253-260.
Go MR, Dundon JM, Karlowicz DJ, Domingo CB, Muscarella P, Melvin WS. Delivery of radiofrequency energy to the lower esophageal sphincter improves symptoms of gastroesophageal reflux. Surgery 2004 Oct;136(4):786-794.
Gould JC, Melvin WS. Computer-assisted robotic antireflux surgery. Surg Laparosc Endosc Percutan Tech 2002 Feb;12(1):26-29.
Melvin WS, Needleman BJ, Krause KR, Schneider C, Ellison EC. Computer-enhanced vs. standard laparoscopic antireflux surgery. J Gastrointest Surg 2002 Jan-Feb;6(1):11-15, discussion 15-16.
